Lynk Pharmaceuticals Announces Clinical Approval In China Of Its New Class I Drug LNK01003
HANGZHOU, China, June 25, 2021 / PRNewswire / – Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), an innovative drug development company, today announced that its new innovative Class I drug, LNK01003, has been approved by the National Medical Products Administration (NMPA) for clinical trials on inflammatory bowel disease (IBD).
LNK01003 is a kinase inhibitor targeting the treatment of inflammatory bowel disease. In preclinical studies, LNK01003 demonstrated the benefits of low systemic exposure and high intestinal exposure, thereby eliminating potential toxicity due to broad suppression of the immune system, and making it a differentiated drug candidate with efficacy and reliability. potentially better security.
“LNK01003 is the third drug candidate developed and approved for clinical studies by the company to date, demonstrating the excellent ability and performance power of Lynk,” said Dr. Zhao-Kui (ZK) Wan, Founder and CEO of Lynk Pharmaceuticals, “We will seek all possibilities to accelerate the clinical development of LNK01003, and we look forward to its clinical performance and hope to bring better and differentiated treatment to patients as soon as possible.”
About Lynk Pharmaceuticals:
Founded in 2018, Lynk Pharmaceuticals is dedicated to the discovery and development of innovative drugs for the treatment of cancer, as well as immune and inflammatory diseases. Lynk Pharmaceuticals was founded by senior drug R&D experts and executives from Pfizer, Merck and Johnson & Johnson. Driven by a higher goal, Lynk Pharmaceuticals aims to be a market leader in meeting unmet medical demands through the development of innovative therapies. To date, Lynk Pharmaceuticals has independently developed a number of innovative Class I clinical drugs and has successfully grown into a clinical stage company. For more information about Lynk Pharmaceuticals, please visit: https://www.lynkpharma.com.
SOURCE Lynk Pharmaceuticals Co., Ltd.